末期性腎臓病患者におけるトランスキャセター大動脈弁置換容量の影響
Esteban Aguayo1, Oh Jin Kwon1, Mitchell Won1
1Cardiovascular Outcomes Research Laboratories (CORELAB), David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA; Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
The Annals of thoracic surgery
|August 29, 2025
まとめ
末期性腎疾患 (ESRD) の患者は,トランスキャテーター大動脈弁置換手術 (TAVR) の後の死亡率と再入院リスクが高くなります. これらのリスクは病院の容量に関係なく存在し,慎重に患者の選択の必要性を強調しています.
科学分野:
- 心血管医学
- 腎臓科
- 介入心臓科
背景:
- 末期性腎疾患 (ESRD) の患者は,大動脈硬化 (calcific aortic stenosis) のリスクが高い.
- ESRD患者におけるトランスキャセター大動脈弁置換 (TAVR) の有効性に関するデータは限られている.
研究 の 目的:
- TAVRを受けたESRD患者の急性死亡率,合併症,および30日間の再入院を調査する.
- ESRDとESRD以外のコホート間の結果を比較する.
主な方法:
- TAVR入院者 (≥18歳) の2016~2021年の国家再入院データベースを利用した.
- ESRDと非ESRDのグループに分けました.
- 病院での死亡率,30日間の再入院,手術後の合併症,入院期間,費用の評価
- 多変数ロジスティック回帰とネルソン・アレン解析を用いて,施設のTAVR量 (低容量 vs 高容量病院) によって層分化した.
主要な成果:
- 41万1,311人のTAVR患者の7. 3%がESRDでした.
- ESRDはリスク調整後,著しく高い死亡率 (AOR1. 79) と再入院率 (AOR1. 87) と関連していた.
- ESRD患者はより長い滞在期間 (+1. 3日) とより高い費用 (+$1. 0K) を経験しました.
- 病院でのTAVRの量は,ESRD患者の死亡率や再入院リスクを軽減しませんでした.
結論:
- TAVRを受けたESRD患者は,手術後の死亡率と再入院のリスクが増加しています.
- より高いTAVRの処置用量センターは,ESRD患者におけるこれらのリスクの上昇を減少させなかった.
- TAVRを受けるESRD患者は,リスクが高まっているため,慎重に患者を選び最適化することが重要です.
関連する概念動画
Continuous Renal Replacement Therapy
129
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
129
Aortic Regurgitation III: Medical Management
42
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
42
Renal Failure: Dose Adjustments
152
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
152
Renal Drug Clearance: Overview
325
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
325
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57


